-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2952 Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo GroupClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, Biological therapies, CLL, Lymphomas, Bispecific Antibody Therapy, Clinical Research, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Romain Guieze, MD, PhD1,2*, Loic Ysebaert, MD, PhD3*, Damien Roos-Weil, MD, PhD4*, Luc-Matthieu Fornecker, MD, PhD5*, Emmanuelle Ferrant, MD6*, Lysiane Molina, MD7*, Thérèse Aurran-Schleinitz, MD8*, Aline Clavert9*, Sophie de Guibert, MD10*, Anne-Sophie Michallet, MD, PhD11*, Alain Saad, MD12*, Bernard Drenou13*, Philippe Quittet, MD14*, Benedicte Hivert, MD15*, Kamel Laribi, MD16*, Julie Gay, MD17*, Julien Broséus, MD PhD18*, Valérie Rouille19*, David Schwartz20*, Bruno Pereira21*, Alain Delmer22 and Pierre Feugier, MD, PhD23,24*

1EA 7453 (CHELTER), Université Clermont Auvergne, Clermont-Ferrand, France
2Department of Hematology, CHU Clermont Ferrand, Clermont Ferrand, MA, France
3Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
4Department of Clinical Haematology, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
5Institut De CancéRologie Strasbourg Europe, Strasbourg, France
6Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre-Bénite, France
7Hématologie clinique, CHU de Grenoble, La Tronche, France
8Institut Paoli Calmettes, Marseille, France
9Department of Hematology, CHU Angers, Angers, France
10Hématologie Clinique, CHU Rennes, Rennes, France
11Centre Hospitalier Lyon Sud, Hospices Civils, LYON, France
12CH Béziers, Béziers, France
13Department of Hematology, CH Mulhouse, Mulhouse, France
14Department of Hematology, CHU Montpellier, Montpellier, France
15Groupement des Hopitaux Institut Catholique de Lille, Lille, France
16Hématologie clinique, CH Le Mans, Le Mans, France
17Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne, France
18Laboratory Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France
19CHU Montpellier, Montpellier, France
20FILO (French Innovative Leukemia Organization), Nancy, France
21Méthodologie – Biostatistique – Data-management, CHU de Clermont-Ferrand, Clermont-Ferrand, France
22Department of Hematology, CHU de Reims, Reims, Cedex, France
23CHRU-Nancy, service d'hématologie biologique, pôle laboratoires, University of Lorraine, Nancy, France
24Hematology Department, University Hospital of Nancy, Vandoeuvre, France


Richter syndrome (RS) is defined as the onset of an aggressive lymphoma, mostly diffuse large B cell lymphoma (DLBCL), in patients with chronic lymphocytic leukemia (CLL). The outcome of RS patients is usually very poor with both low response rates to chemoimmunotherapy and short survival. Modulating anti-tumor immunity has been suggested as a promising approach in RS (Ding, Blood 2017; Younes Lancet Hematol, 2019)). Blinatumomab is a bi-specific T-cell engaging antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent lysis of tumor cells. It has been been evaluated in patients with R/R DLBCL and demonstrated promising results (ORR 43%) with acceptable safety (Viardot, 2016).

We hypothesized that blinatumomab would improve response in RS patients failing to achieve CR after initial debulking with R-CHOP.


We report here the final results of a phase 2 multicenter and prospective study investigating the efficacy and safety of blinatumomab after R-CHOP debulking therapy for patients with untreated RS of DLBCL histology (NCT03931642). The patients with persisting (PR, SD) or progressive disease (PD) after 2 cycles of R-CHOP were eligible to receive an 8-week course of blinatumomab induction. Blinatumomab was administered at a stepwise dose of 9 μg/d in the first week, 28 μg/d in the second week, and 112 μg/d thereafter. The primary endpoint was CR rate according to the revised Lugano criteria after the 8-week induction course of blinatumomab. An additional 4-week consolidation cycle was optional. Allo-HSCT was further allowed for eligible patients.


A total of 41 patients were enrolled in the trial and the final analysis set includes 39 patients who started on first cycle of R-CHOP. Median age was 66 years (range, 38-82) and sex ratio M/F was 26/13. CLL genetic features at baseline were as follows : 18/30 (60%) had 17p deletion, 20/31 (64%) TP53 mutations and 20/32 (63%) had complex karyotype. Median number of prior therapeutic lines for CLL was 2 (range, 0-7): 19 (54%) patients previously received chemo-immunotherapy, 23 (59%) patients were exposed to ibrutinib including 11 (28%) also exposed to venetoclax. Regarding RS features, 33 (90%) patients presented with advanced RS disease (Ann Arbor staging) and IPI was 0-1 for 2 (5%), 2-3 for 28 (72%) and 4-5 for 9 (23%) patients

As of the data cut-off of June 1st, 2022, the blinatumomab induction course has been completed for 25 patients. Fourteen patients did not receive blinatumomab for the following reasons: 9 patients achieved CR after R-CHOP, 1 patient progressed while on first cycle of R-CHOP, 3 patients died (2 because of febrile neutropenia and 1 following intracranial hemorrhage) after R-CHOP and 1 patient presented severe pneumonia after R-CHOP.

Regarding toxicity during blinatumomab induction, all patients had at least one grade 1 adverse event (AE), 9 had grade ≥3 AE. The most common all grade TEAE (> 1 case), regardless of relationship to blinatumomab, included fever (40%), CRS (16%), headache (16%), paresthesia (12%), cholestasis (12%), sepsis (8%), vein thrombosis (8%), dyspnea (8%), diarrhea (8%), constipation (8%). Grade >2 hematological toxicity was as follows : anemia (8%), neutropenia (4%) and thrombocytopenia (4%). In terms of neurologic events, 16 (64%) experienced neurotoxicity while grade >2 TEAE were seen only in 2 patients. All but one (confusion) recovered. Blinatumomab was temporarly stopped in 3 patients and permanently in 2.

In terms of efficacy, after completion of R-CHOP debulking therapy (n=34 evaluable patients), 9 patients achieved CR, 10 patients were in PR, 4 patients were stable and 11 patients were progressive. At evaluation after the blinatumomab induction (n=25 evaluable patients), 5 (20%) patients achieved CR, 4 (16%) patients PR, 6 (24%) patients were stable. Considering the whole strategy (including R-CHOP debulking) (n=39), 18 (46%) patients achieved overall response and 14 (36%) CR.


The BLINART trial met its primary endpoint by showing that blinatumomab induces significant CR rate in patients with RS failing to achieve CR after R-CHOP debulking. Blinatumomab demonstrates encouraging anti-tumor activity and acceptable toxicity in patients with RS. Our study opens a new avenue for further immunotherapy strategies with bispecific antibodies in RS.

Disclosures: Guieze: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astrazeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie, Beigene, Janssen, Gilead, Roche, AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ysebaert: Abbvie, Astra-Zeneca, Janssen, Roche, Beigene, BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. de Guibert: Janssen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Laribi: AbbVie, AstraZeneca, Beigene, Iqone, Janssen, Novartis, Takeda: Honoraria. Broséus: Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Astra Zeneca: Consultancy, Honoraria; Gilead: Honoraria. Delmer: Takeda: Honoraria; Novartis: Honoraria; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Abbvie: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support. Feugier: AstraZeneca, Janssen, Abbvie, Beigene, Gilead: Membership on an entity's Board of Directors or advisory committees, Other: Congress Invitations.

OffLabel Disclosure: Blinatumomab is approved for acute lymphoblastic leukemia. The present work had evaluated this drug in Richter syndrome.

*signifies non-member of ASH